Activity of various endogenous compounds and pharmacologic agents at a glucose-oxidizing platinum electrode

The specificity of a glucose-oxidizing platinum electrode system was investigated in vitro using selected metabolic compounds and a wide range of pharmacologic agents. Many compounds were found that either augmented or inhibited the glucose effect on the electrode system, but relatively few had substantial effects at reasonable plasma levels. Should the platinum electrode system be incorporated into an artificial beta cell for diabetic patients, graduated clinical trials might be necessary for every new medication taken by the patients.